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Abstract
Purpose: The purpose of this case report is to bring to light this unusual combination of two rare diseases, namely
Neimann-Pick disease Type B and clear cell chondrosarcoma occurring in the same patient. This has not previously been
reported in the world literature.
Subject: Niemann-Pick disease (NPD) is a rare autosomal recessive inborn error of metabolism. Type B NPD is even rarer.
It is a lysosomal storage disorder affecting children and adolescents often causing death in early childhood, although in
milder form patients may survive up to adulthood, like our patient. Clear cell chondrosarcoma is a very rare type of
chondrosarcoma affecting the epiphyseo-metaphyseal region of long bones. We present a patient suffering from a milder
form of Neimann Pick disease who developed a clear cell chondrosarcoma. We investigated to find if there was likely to be
any relationship between these two events.
Results: NPD type B is caused by a three-base deletion in chromosome 11. Chondrosarcoma and multiple exostoses occur
due to loss of tumour suppressor gene EXT 2 from centromeric region on chromosome 11, though it is difficult to establish
the link between the two, as the two together have not yet been reported in the literature. NPD may present diagnostic
difficulties when it occurs with chondrosarcoma.
Discussion: We conclude that the two diseases have not been reported together in the world literature and there is some
evidence to show that chromosome 11 is central to both diseases. More research is needed to see if one leads to the other.
Introduction
Niemann-Pick disease (NPD) is a rare autosomal
recessive inborn error of metabolism, a lysosomal
storage disorder characterized by deficiency of acid
sphingomyelinase. Acid sphingomyelinase is an
enzyme metabolising cell membrane lipid sphingo-
myelin. This leads to sphingomyelin deposition in the
lysosomes of cells in brain, reticuloendothelial and
lung tissue [1]. Chondrosarcoma is a rare slow-
growing malignant tumour of bone producing
cartilage matrix, common in the the fifth and sixth
decades [2]. These two diseases have not been
reported together as patients with NPD usually die
early and chondrosarcoma is common after the fifth
decade.
Case report
A 50-year-old right-handed maintenance engineer
presented with a 4-week history of left elbow pain.
It was initially diagnosed as tennis elbow but no
X-rays were taken. He later sustained a pathological
fracture of his left olecranon while opening a
door (Figure 1). This fracture was internally fixed
by the referring hospital but a sample taken at the
time of surgery revealed a chondrosarcoma and
hence he was sent to the oncology service at our
hospital.
He had a history of NPD as a child and had
splenomegaly and interstitial lung disease but
otherwise had no signs of manifestation of the
disease.
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of 30–90 of flexion with full supination and
pronation. Neurovascular status of the left upper
limb was normal. Magnetic resonance imaging of his
left elbow showed an effusion in the joint and not
much else due to the implant. Computer tomography
and bone scintiagraphy showed no evidence of
metastases.
The patient opted for an above elbow amputation
because of the high risk of local recurrence with limb
salvage surgery especially in view of the intra-
articular disease and previous surgery. Histology of
the amputated limb showed a grade II conventional
chondrosarcoma mixed with foci of clear cell
chondrosarcoma of the left proximal ulna with wide
amputation margins (Figure 2). The patient has
subsequently developed multiple lung metastases.
Results
We did a literature search to understand the nature
of the two diseases, probed if there were any genetic
link between the two and if one can influence the
presentation, progression and prognosis of the other.
NPD type B is caused by delta 608 mutation, a three-
base deletion in chromosome 11 that causes the
removal of an arginine residue from position 608 of
the ASM polypeptide [3]. Chondrosarcoma and
multiple exostoses occur due to loss of tumour
suppressor gene EXT 2 from centromeric region on
chromosome 11 by base deletion as one of the
mechanism [4], though it is difficult to establish the
link between the two with available research in
molecular genetics. Though we could not prove that
one can influence the progression and prognosis of
the other, certainly NPD produces interstitial lung
disease which could present diagnostic difficulties in
ruling out pulmonary metastases by imaging, as
happened in our patient where initially diagnosed
interstitial lung disease in the follow-up CT proved
to be lung secondaries from chondrosarcoma
(Figures 3 and 4).
Discussion
NPD is an inborn error of metabolism, leading
to deposition of lipid in the lysosomes of cells
[1,5]. Histologically large pale foamy cells are seen
in the reticuloendothelial system, which stain posi-
tively with lipid stains. The gene for acid sphingo-
myelinase is carried on chromosome 11, mutations
of which cause decreased production of the active
enzyme [3,6].
There are three types of NPD. Type A disease
has less than 5% of active enzyme, and is a rapidly
progressive neurodegenerative disease of infancy
Figure 1. Lateral Radiograph elbow. This shows a pathological
fracture of the olecranon. Features are that of an aggressive lesion
but are otherwise non-specific.
Figure 2. Low power photomicrograph. This shows areas of
grade II conventional chondrosarcoma (right half of the field)
invading host bony trabeculae and showing clear cell change
(left half of the field).
Figure 3. Computed tomography of the chest. This shows lung
window images of lung bases showing reticulo-nodular pattern.
These ill-defined changes are suggestive of interstitial lung disease
though miliary metastases are difficult to rule out.
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retardation, feeding problems, progressive spasticity,
blindness with cherry red spot, hepato-splenomegaly,
jaundice of infancy with progressive liver failure and
death. Most patients die by the age of 2–3 years.
Type C is also a severe form and due to defective
cholesterol transport, trapping sphingomyelin and
cholesterol inside cells with central nervous system
involvement leading to seizures and death by 5–15
years of age.
Type B, as seen in this case, is a milder form with
5–10% of acid sphingomyelinase activity and patients
live up to late childhood and adulthood, like our
patient. It is characterised by reticuloendothelial
system sphingomyelin deposition leading to hepato-
splenomegaly and pulmonary involvement with an
absence of neurological manifestation and survival
into adulthood [6,7].
Diagnosis of NPD is by enzyme assay of
acid sphingomyelinase from peripheral blood
WBCs or from cultured skin fibroblasts. Prenatal
diagnosis by amniocentesis is possible. At present
most of the available treatments are preventive [8],
supportive or experimental. These include enzyme
replacement therapy, gene therapy, and bone
marrow transplant.
Chondrosarcoma is a rare malignant bone tumour
producing cartilage matrix common in the fifth and
sixth decade with a male to female ratio of 3:2. Our
patient had a clear cell chondrosarcoma with asso-
ciated classical grade II chondrosarcoma. Clear cell
chondrosarcoma is also called ‘malignant chondro-
blastoma’. It represents about 2% of malignant
cartilaginous bone tumours with a male to female
ratio of 3:2. It commonly affects the proximal femur
or tibia and only rarely the ulna. Histologically it
shows sheet-like non-lobular arrangement of cartila-
ginous cells with tumour cells showing abundant
clear cytoplasm and distinct cell borders due to
paucity of organelles and a cytosol with low protein
content in these cells. The presence of a spectrum of
immature chondroblasts to mature chondrocytes is
characteristic of clear cell chondrosarcoma.
Radiologically it shows as an ephiphyseal osteolytic
and expansile lesion. More than 50% of these
tumours do not show calcification. As soft
tissue invasion is rare this tumour has a good
prognosis. A combination of clear cell and classical
chondrosarcoma is not uncommon, whilst dediffer-
entiated clear cell chondrosarcoma has also been
reported [10].
The treatment of chondrosarcoma is usually
surgical with wide local excision. Radiotherapy and
chemotherapy are not effective. If the tumour is
incompletely excised it has a high incidence of local
recurrence and subsequent metastasis [11,12].
It was difficult to prove that one leads to the
other, though more research in molecular genetics
probing this problem may well establish a link in the
future. Although chondrosarcoma is associated with
altered carbohydrate metabolism [12], we could not
prove that one can influence the progression and
prognosis of the other; however, NPD does produce
interstitial lung disease, which could present diag-
nostic difficulties in ruling out pulmonary metastases.
With the presently available evidence, the two
diseases arising together appears to be a chance
occurrence.
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